72
Participants
Start Date
January 31, 2014
Primary Completion Date
September 30, 2015
Study Completion Date
October 31, 2015
NNZ-2566
Glycyl-L-2-Methylpropyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (2g in 50mL vials or 3g in 30mL bottles) for reconstitution with strawberry flavored solution 0.5% v/v in Water for Injection.
Placebo
Strawberry flavored solution
Mount Sinai School of Medicine, New York
Autism & Developmental Medicine Institute Geisinger Health System, Lewisburg
Suburban Research Associates, Media
Children's National Hospital, Washington D.C.
Kennedy Krieger Institute, Baltimore
Greenwood Genetic Center, Greenwood
Emory University, Atlanta
Vanderbilt University Medical Center, Nashville
Cincinnati Children's Hospital Medical Center, Cincinnati
University of Michigan, Ann Arbor
Rush University Medical Center, Chicago
University of Nebraska, Omaha
Texas Children's Hospital, Houston
Children's Hospital Colorado, Denver
UC Davis MIND Institute, Sacramento
Seattle Children's Hospital, Seattle
University of Massachusetts Medical School, Worcester
Lead Sponsor
Neuren Pharmaceuticals Limited
INDUSTRY